We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.
- Authors
VAN MUIJEN, Marloes E.; THOMAS, Sarah E.; VELLINGA, Douwe; BOUWMAN, Silke; VAN DOORN, Martijn B. A.; POLITIEK, Klaziena; OTERO, Marisol E.; VAN DEN REEK, Juul M. P. A.; DE JONG, Elke M. G. J.
- Abstract
The article presents a study which aims to evaluate 1- and 2-year drug survival (DS) of guselkumab, split for discontinuation due to ineffectiveness or side-effects. It mentions that the study elucidate predictors for a shorter guselkumab DS. It informs that guselkumab has been registered as the first interleukin-23 (IL-23) inhibitor for treatment of psoriasis.
- Subjects
PSORIASIS; PSORIATIC arthritis; TYPE 2 diabetes
- Publication
Acta Dermato-Venereologica, 2022, Vol 102, p1
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/actadv.v102.685